Chintan V Dave1,2, Sebastian Schneeweiss3, Deborah J Wexler4, Gregory Brill3, Elisabetta Patorno3. 1. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA cdave@bwh.harvard.edu. 2. Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ. 3. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 4. Massachusetts General Hospital Diabetes Center and Harvard Medical School, Boston, MA.
Abstract
OBJECTIVE: There is a paucity of data evaluating recent changes in clinical and prescriber characteristics of patients initiating sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA). RESEARCH DESIGN AND METHODS: U.S.-based administrative claims data (July 2013 to June 2018) were used to identify initiators of SGLT2i and GLP-1RA. RESULTS: Over 5 years, empagliflozin initiation (as a proportion of SGLT2i) increased by 57.1% (P < 0.001 for trend), while canagliflozin initiation declined by 75.1% (P < 0.001). Empagliflozin was the only agent within SGLT2i with an increase in the proportion of patients with myocardial infarction, stroke, or heart failure (collectively called CVD-HF) (P < 0.001). Liraglutide initiation (as a proportion of total GLP-1RA) declined by 32.1% (P < 0.001), and dulaglutide initiation increased by 34.1% (P < 0.001); the proportion of patients with CVD-HF increased the most in liraglutide initiators (5.1% increase; P < 0.001). Most prescribers were internists or endocrinologists; cardiologist prescribing remained low (<1%). CONCLUSIONS: For SGLT2i, shifts in preference for empagliflozin followed changes in drug labels and guidelines, while for GLP-1RA, other factors such as price or ease of administration may have led to a preference for dulaglutide over liraglutide.
OBJECTIVE: There is a paucity of data evaluating recent changes in clinical and prescriber characteristics of patients initiating sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA). RESEARCH DESIGN AND METHODS: U.S.-based administrative claims data (July 2013 to June 2018) were used to identify initiators of SGLT2i and GLP-1RA. RESULTS: Over 5 years, empagliflozin initiation (as a proportion of SGLT2i) increased by 57.1% (P < 0.001 for trend), while canagliflozin initiation declined by 75.1% (P < 0.001). Empagliflozin was the only agent within SGLT2i with an increase in the proportion of patients with myocardial infarction, stroke, or heart failure (collectively called CVD-HF) (P < 0.001). Liraglutide initiation (as a proportion of total GLP-1RA) declined by 32.1% (P < 0.001), and dulaglutide initiation increased by 34.1% (P < 0.001); the proportion of patients with CVD-HF increased the most in liraglutide initiators (5.1% increase; P < 0.001). Most prescribers were internists or endocrinologists; cardiologist prescribing remained low (<1%). CONCLUSIONS: For SGLT2i, shifts in preference for empagliflozin followed changes in drug labels and guidelines, while for GLP-1RA, other factors such as price or ease of administration may have led to a preference for dulaglutide over liraglutide.
Authors: Muthiah Vaduganathan; Vasanth Sathiyakumar; Avinainder Singh; Cian P McCarthy; Arman Qamar; James L Januzzi; Benjamin M Scirica; Javed Butler; Christopher P Cannon; Deepak L Bhatt Journal: J Am Coll Cardiol Date: 2018-12-25 Impact factor: 24.094
Authors: Sandeep R Das; Brendan M Everett; Kim K Birtcher; Jenifer M Brown; William T Cefalu; James L Januzzi; Rita Rastogi Kalyani; Mikhail Kosiborod; Melissa L Magwire; Pamela B Morris; Laurence S Sperling Journal: J Am Coll Cardiol Date: 2018-11-26 Impact factor: 24.094
Authors: Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews Journal: N Engl J Med Date: 2017-06-12 Impact factor: 91.245
Authors: Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman Journal: N Engl J Med Date: 2016-06-14 Impact factor: 91.245
Authors: Muthiah Vaduganathan; Ravi B Patel; Avinainder Singh; Cian P McCarthy; Arman Qamar; James L Januzzi; Benjamin M Scirica; Javed Butler; Christopher P Cannon; Deepak L Bhatt Journal: J Am Coll Cardiol Date: 2019-04-02 Impact factor: 24.094
Authors: Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse Journal: N Engl J Med Date: 2016-06-13 Impact factor: 176.079
Authors: Elisabetta Patorno; Phyo T Htoo; Robert J Glynn; Sebastian Schneeweiss; Deborah J Wexler; Ajinkya Pawar; Lily G Bessette; Kristyn Chin; Brendan M Everett; Seoyoung C Kim Journal: Ann Intern Med Date: 2021-09-28 Impact factor: 25.391
Authors: Rishav Adhikari; Kunal Jha; Zeina Dardari; James Heyward; Roger S Blumenthal; Robert H Eckel; G Caleb Alexander; Michael J Blaha Journal: J Am Heart Assoc Date: 2022-04-27 Impact factor: 6.106
Authors: Jing Luo; Robert Feldman; Scott Rothenberger; Mary Korytkowski; Michael A Fischer; Walid F Gellad Journal: J Gen Intern Med Date: 2022-01-19 Impact factor: 6.473
Authors: John R Petrie; James G Boyle; Kashif Ali; Christopher Smith; Deborah Morrison; Partha Kar Journal: Diabet Med Date: 2020-11-17 Impact factor: 4.213
Authors: Kristian L Funck; Jakob S Knudsen; Troels K Hansen; Reimar W Thomsen; Erik L Grove Journal: Diabetes Obes Metab Date: 2020-11-17 Impact factor: 6.577